Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

(PRNewsfoto/科济药业)

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line (1L) treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA), have been presented as a poster presentation at the 2026 ASCO Annual Meeting on May 30, 2026, 13:30 – 16:30, CDT. The poster was titled "Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a subgroup analysis" [1].

Recommended for you